加载中........
×

MedSci 2019年期刊智能查询系统(2018年度)

期刊关键词: 支持模糊智能搜索,多关键词组合

期刊领域: 可留空

IF范围: 小于 大于 填数字,填写自己想选择的杂志影响因子范围,可留空

排列方式: 文章数量往往与发表的周期有关

注册会员 APP首发更新 在线咨询

    以下是对 J THORAC ONCOL 杂志介绍
    缩写名/全名
    J THORAC ONCOL/journal of thoracic oncology
    投稿经验 | 期刊论坛 | Medsci期刊指数 | 中国SCI文章 | 杂志简介 | 杂志主页  | 投稿链接  | 作者需知  | PMC链接
    ISSN号 1556-0864
    1556-1380(电子版ISSN)
    被收录情况 Science Citation Index
    Science Citation Index Expanded
    Current Contents - Clinical Medicine
    出版周期 Monthly
    H指数 102 (google发布,2017年度)
    CiteScore分区 所属分类:Medicine - Pulmonary and Respiratory Medicine 分区: 2/134|Medicine - Oncology 分区: 29/32
    CiteScore趋势 5.71 (2018年度)
    APP下载
    相关报道 · J Thorac Oncol:放疗分割方式是否与脑转移相关?III期临床研究CONVERT给你答案
    · JTO:病例分享——见微知著,KRAS突变肺腺癌转化为小细胞肺癌是免疫治疗的耐药机制?
    · JTO:淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系,它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后?
    · J Thorac Oncol:免疫检查点抑制剂治疗NSCLC 肺炎偶发or频频造访?
    · JTO:低剂量CT在非吸烟者肺癌筛查中的意义
    · JTO:RAF突变NSCLC靶向和免疫治疗均有效
    · J Thorac Oncol:掀起免疫治疗NSCLC继发耐药的神秘面纱
    · J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗?
    · J Thorac Oncol:局部晚期NSCLC的首发失败部位风险模型
    · J Thorac Oncol:Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC: MARQUEE研究亚组分析
    出版社或管理机构杂志由  Elsevier  出版或管理。    ISSN号:1556-0864
    杂志简介/稿件收录要求Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.
    杂志主页/投稿链接journal of thoracic oncology 主页  (点击10544次)  | 投稿链接(点击2181次)
    常用链接

    免费全文(pubmed central) | 投稿经验 | Medsci期刊指数 | 杂志主页 | 投稿链接 |

    web对话